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It is well recognised that polycystic ovary syndrome 
(PCOS) is the most common endocrinopathy in women in 
their reproductive years, affecting 5 - 10% of this segment 
of the population.
The current diagnosis of PCOS is based on the Rotterdam 
consensus statement 2003,1 and is based on three main 
criteria:
• oligo- or anovulation
•  clinical or biochemical signs of hyperandrogenism (with 
exclusion of congenital adrenal hyperplasia, Cushing’s 
syndrome, androgen-secreting tumours, thyroid 
abnormalities and hyperprolactinaemia)
• polycystic ovaries on ultrasound.
To diagnose PCOS, and bearing in mind that it is a 
syndrome and does not exist as a single symptom, two 
of the three criteria must be present.
When a woman presents with PCOS, clinicians usually 
concentrate on treating infertility if she desires a 
pregnancy. Since PCOS has recently been recognised 
as an endocrinopathy with metabolic disturbances, it is 
appropriate to modify the goal of treatment, which is to 
prevent the long-term effects. PCOS is associated with 
an array of metabolic disturbances (hyperinsulinaemia 
and insulin resistance, dyslipidaemia, hypertension and 
cardiovascular disease) as well as an increased risk of 
neoplasia in affected patients who are not managed 
appropriately.2
It has been established that several factors influence 
the presentation of PCOS. Diet and lifestyle may play a 
role.3
Pathogenesis
Environmental factors are also significant in the 
pathogenesis. Fetal undernutrition results in intrauterine 
growth adaptation and increases the prevalence of 
coronary heart disease, stroke, hypertension and type 2 
diabetes mellitus in later life.4 This finding is based on 
the Barker hypothesis. Barker and Clark demonstrated in 
1997 that size at birth is related to the risk of developing 
disease in later life. In particular, connections between 
reduced birth weight, increased risk of coronary heart 
disease, hypertension, diabetes and stroke in adulthood 
are well established.5 These relationships are modified by 
patterns of postnatal growth. The most widely accepted 
mechanisms thought to cause these relationships are 
those of fetal programming by nutritional stimuli or excess 
fetal glucocorticoid exposure. It has been suggested that 
the fetus makes physiological adaptations in response to 
changes in its environment to prepare itself for postnatal 
life. These changes may include epigenetic modification 
of gene expression. Currently, active research in this field 
will have direct relevance to future obstetric practices.
Today’s challenge
It is clear that gynaecologists need to be aware of the 
long-term complications in their patients, and to pay 
attention to modifiable factors. They should have a holistic 
approach to patients with PCOS and not only deal with 
their reproductive issues such as menstrual dysfunction, 
complaints of hyperandrogenism, and infertility.
Evidence-based medicine should be the cornerstone of 
clinical practice. Appropriately designed longitudinal 
studies are usually not available, and most of the available 
information on the risks and prevalence of long-term 
outcomes of PCOS depends on case-series reports, non-
randomised studies using historical controls, and non-
randomised studies with a concurrent control group.
According to the work of Norman and colleagues, it is 
very important to obtain a family history, since insulin 
resistance is common in apparently unaffected relatives 
of women with PCOS.6 Events in the patient’s own 
intrauterine period should be recorded if available. 
Environmental factors and the patient’s lifestyle should 
be taken into consideration.
Long-term risks
Hyperinsulinaemia and insulin 
resistance
Insulin resistance is defined as the body’s inability to deal 
with a normal glucose load or the inability of insulin to 
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exert its physiological effect. This is a problem in obese 
and non-obese women with PCOS.2 Dahlgren did a follow-
up on women for 11 years and demonstrated that women 
with PCOS are more likely to develop type 2 diabetes 
mellitus.
Insulin increases the action of luteinising hormone (LH) on 
theca cells, resulting in overproduction of androgens. The 
overall result of hyperinsulinaemia and insulin resistance 
on the ovaries is that of anovulation and the appearance 
of acanthosis nigricans owing to hyperandrogenic effects 
on the skin and abnormal hepatic function, especially 
decreased sex hormone-binding globulin (SHBG), resulting 
in increased free bio-available testosterone.7
Insulin resistance seems to be more than just a marker 
for future diabetic risk – it is also significant in the 
pathophysiology of PCOS and cardiovascular risks.
Reaven8 described syndrome X, also known as metabolic 
syndrome, which is characterised by lipid abnormalities, 
hypertension, central obesity and abnormalities in 
glucose dynamics. It is frequently evident that PCOS and 
metabolic syndrome coexist in the same patient. Glueck 
et al.9 reported a 46% prevalence of metabolic syndrome 
in women with PCOS, compared with 23% in the general 
population over the age of 20 years.
Given the significant morbidity and mortality risk, the 
importance of screening all women with PCOS for these 
associated diseases and assuring further management10 
is again illustrated.
Obesity
Obesity is a complex problem with far-reaching effects 
and serious health implications. Associated with obesity 
is an increased risk of psychosocial impairment, type 2 
diabetes mellitus, cardiovascular disease, osteoarthritis, 
sleep apnoea, and uterine cancer.11 The significant impact 
that all these conditions can have on our economy is 
notable.
A range of research methods is available for precise 
measurement of the amount and localisation of fat and 
lean mass, e.g. skinfold thickness, underwater weighing, 
dual energy X-ray absorptiometry, magnetic resonance 
imaging (MRI) and infrared spectroscopy. However, a 
simple and reliable definition of obesity is needed for the 
clinical setting. Body mass index (BMI) is a useful clinical 
tool that correlates well with adiposity (Table I).12
The well-known classification adapted from the work of 
JC Seidell in 1995 is used in the clinical setting to help 
establish the risk of co-morbidity.13
The waist-hip ratio is an easy and practical tool to use. It 
provides a reasonable estimate of abdominal fat without 
distinguishing between visceral or subcutaneous fat.14 A 
ratio ≥0.8 in women and 0.9 in men indicates an increased 
risk for cardiovascular disease.15
In 2001, Dobbelsteyn et al.16 suggested another clinical 
measuring tool – waist circumference (Table II), which 
is measured midway between the lowest rib and the 
iliac crest. It predicts risk of metabolic complications 
associated with obesity. If a patient falls in the increased 
risk group, this finding should alert the clinician to the 
potential risk of cardiovascular disease. If a patient falls in 
the substantially increased risk group, therapeutic action 
should be initiated.17
According to a local report by the Medical Research Council 
(MRC), obesity is becoming an enormous problem.18 This 
study by Puoane et al. revealed that the situation in South 
Africa is similar to the American epidemic.
In a sample of 7 726 South African women aged 15 - 95 
years, black women had the highest prevalence of obesity, 
followed by women of mixed ancestry, with white women 
in the third position. Indian women had a prevalence of 
48.9%. Urban women had a slightly higher BMI compared 
with their rural counterparts; BMI in both groups was 
found to increase with age.18
The African continent is known for malnutrition; 
however, the picture is changing (Table III). Obesity 
is not only a problem of developed nations but is also 
becoming an increasing problem in countries undergoing 
epidemiological transition, such as South Africa, Mexico 
Classification  BMI   Risk of co-morbidities
Underweight  <18.5   Low (but risk of other clinical problems increased)
Normal range  18.5 - 24.9  Average
Overweight  ≥25   Moderate
Pre-obese  25 - 29.9   Increased
Obese class 1  30.0 - 34.9  Moderate
Obese class 2  35 - 39.9   Severe
Obese class 3  ≥40   Very severe
Table I.      Classification of overweight in adults according to body mass index (BMI)
  Increased  Substantially
  risk  increased risk
Men   ≥94 cm   ≥102cm
Women   ≥80cm   ≥88cm
Table II.      Waist circumference predicts risk of 
metabolic complications associated 
with obesity (adapted from Seidell13)
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and South America.18 In South Africa, where malnutrition, 
poverty and epidemic infectious disease are widespread, 
the problem of obesity could be viewed as less pressing. 
According to these current statistics, however, a 
significant problem of overnutrition in adults and young 
women exists; urban black women are at greatest risk.
Different abdominal fat regions may additionally 
confer differing risks, with evidence suggesting that 
abdominal visceral fat correlates more strongly with 
insulin resistance and markers of metabolic syndrome, 
whereas subcutaneous fat has a far lower risk profile. This 
observation was confirmed by Yamashita et al.20
In a study by Hartz et al.,21 it was found that the relative 
risk of irregular menstruation and oligomenorrhoea in 
women with upper body fat predominance was 1.56 and 
2.29 respectively, compared with women with lower body 
fat predominance.
Further studies are needed to distinguish between the 
effects of visceral and subcutaneous fat.
The link between obesity and infertility is complex. In 
addition to altered gonadotrophin levels, obese women 
exhibit varied reproductive hormone profiles;22 they have 
increased serum androgen levels, especially testosterone 
and androstenedione, as well as reduced SHBG levels. 
Extensive work by Pasquali et al.,23 Seidell et al.24 and 
Holte et al.25,26 demonstrated that abdominal fat is related 
to decreased SHBG and increased androgenicity.
Convincing evidence23,25,27,28 exists to confirm the strong 
association between obesity, abdominal obesity and 
insulin resistance. Increased androgen production and 
reduced binding of androgens to SHBG contributes to 
hyperandrogenism, resulting in anovulation through 
inhibition of follicle maturation.
Work by Poretsky and Kalin29 and by Plymate et al.30 indi-
cates that hyperinsulinaemia increases ovarian androgen 
production and decreases SHBG, with significant effect 
on PCOS. A study by Dunaif et al.7 supported that insulin 
resistance is consistently documented in lean and obese 
women when compared with weight-matched controls. 
Obesity and abdominal obesity may therefore contrib-
ute to the already altered hormonal profile of women 
with PCOS, with a further increase in the prevalence 
of anovulation, menstrual irregularities and infertility.
Other systems affected
It has become apparent that PCOS is associated with 
multiple risk factors for cardiovascular disease. The 
risk factors include hypertension, dyslipidaemia, 
                    Age in years
Country Sex 5 - 14 15 - 29 30 - 44 45 - 59 60 - 69 70 - 79 80+
Cameroon M 243.7 24.4 24
F 24.6 24.8 25
Ethiopia M 14.2 17.5 18.3 18 18 17.9 19.8
F 14.5 18.9 18.6 17.3 16.7 17.6 18.6
Gambia M 19.6 20.5 20.9 21 20
F 21 21.9 21.8 21.3 20.9
Ghana M
F 21.8 22.4 21.4
Kenya M
F 21.7 22.3 22
Malawi M 19.8 19.8 19.7
F 20.5 20.5 19.6
Mali M 18.9 20.5 20.8 20.3 19.6 20.2
F 19.9 21.1 20.6 20 19.5 20.8
Nigeria M 19.8 20.9 21.5
F 21 21.8 20.3
Senegal M 18.2 19.9 21 20.7 19.8 19.2
F 19.6 21.4 22.1 22.2 21.3 20.7
Seychelles M 22.9 23.5 23.1 23.2
F 23.2 25.7 27.2 27.5
South Africa M 13.8 21.5 24.2 25.3 24.8 24.4
F 14 24.4 28.5 29.9 28.8 27.7
Tanzania M
F 21.8 22.3 21.6
Zimbabwe M 15.3 19.5 20.8 21 21 20.1 20
F 15.4 21.3 23 23.5 21.8 20.5 20.3
Table III.     Mean BMI of African countries categorised by age and gender (adapted from International 
Obesity Task Force: Global Burden of Disease Analyses 200219)
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coagulation abnormalities, endothelial dysfunction and 
hyperhomocysteinaemia.31
Bengtsson et al.32 published their findings on lipid 
abnormalities in women with PCOS. This study took place 
in Gothenburg over 20 years and demonstrated that an 
increased serum triglyceride concentration and central 
obesity is associated with an increase in mortality. Work 
by Robinson et al.33 and Wild34 confirmed these findings 
that an abnormal lipid profile can ultimately influence 
morbidity in the long term.
Dahlgren2 reviewed women with PCOS over a period of 
decades and found that hypertension was a common 
diagnosis among women with PCOS. Another study from 
Amsterdam35 confirmed the presence of hypertension in 
women with PCOS and linked it to the presence of obesity 
in ageing women with PCOS.
Evidence has shown that disruption or alteration of 
coagulation and fibrinolytic factors in PCOS may affect 
cardiovascular risk. A study on endothelial function 
by Talbott et al.36 suggested that endothelin-1, as an 
indicator of vasculopathy, is elevated in PCOS. Current 
opinion supports the view that plasminogen activator 
and vascular reactivity implicate PCOS in the evolution 
of cardiovascular disease.37
A buzzword of the new millennium was homocysteinae-
mia, and the work of Loverro et al.38 published in 2002 
demonstrated hyperhomocysteinaemia in women with 
PCOS, which may lead to increased risk for cardiovas-
cular disease. Homocysteine levels appear to vary with 
ethnicity and correlate with insulin levels.31 Diastolic 
dysfunction, in association with hyperhomocysteinae-
mia, are risk factors contributing to cardiovascular risk.39
Birdsall et al.40 demonstrated clinical evidence of an 
association between cardiovascular disease and PCOS. 
In this study, women <60 years underwent coronary 
angiography, and 42% were found to have PCOS. 
These women also had associated hirsutism, increased 
testosterone and abnormal lipid profiles. The extent of 
their coronary artery disease was also far worse than 
that of unaffected patients. These results suggested that 
PCOS carries a risk for coronary artery disease. It remains 
important to be aware of these risk factors but to bear in 
mind that they do not have a predictive value.
Cancer risk
Women with PCOS have a risk of developing a hormone-
dependent carcinoma.41 Undoubtedly, they have an 
increased risk for endometrial carcinoma owing to 
unopposed oestrogen levels.42 Risk for breast cancer and 
benign disease of the breast have not been confirmed.43
Dahlgren2 and Hardiman et al.44 advised that women known 
to have PCOS and subsequent anovulatory cycles should 
receive endometrial protection, and serial follow-up was 
advised to detect endometrial hyperplasia. Screening for 
endometrial hyperplasia has long been known to prevent 
progression to endometrial carcinoma. However, no good 
data are available to support the increased risk for breast 
cancer in women with PCOS. Most studies have failed to 
demonstrate a particular risk for breast cancer in these 
women with a hyperoestrogenic state.45 Cattral and 
Healy46 published a study, but their data did not support an 
increased risk for ovarian carcinoma in PCOS patients.
Management
The mainstay of therapy is to treat obesity. This 
statement implies adequate weight loss as a precursor 
to pharmacological intervention. Reduction of visceral and 
abdominal fat will result in an improvement of menstrual 
function and lessened infertility, resulting in decreased 
metabolic risks.47 Insulin resistance will also be reduced.26 
Women with PCOS need to be treated properly, in their 
reproductive years as well as in the postmenopausal 
period.
Weight reduction is no easy task. One needs to be realistic 
in planning this strategy. Each patient should be treated 
individually. It is of utmost importance that the patient 
is co-operative and motivated. Most women with obesity 
have a psychosocial barrier and need to be treated with 
respect and understanding. They need to understand the 
reason for this initial therapy and how their general health 
will benefit when losing the desired amount of weight.
One question is: how much weight loss is the goal? 
Hollmann et al.48 as well as Clark and co-workers47,49 
showed that only a small amount of weight loss is needed 
for resumption of ovulatory function. As little as 2 - 5% 
reduction of body weight was associated with restoration 
of ovarian function, an 11% reduction of abdominal fat, 
a 4 cm waist circumference reduction and the added 
benefit of a 71% increase in insulin sensitivity.47,49 It is 
therefore not necessary to lose large amounts of weight 
to regain reproductive function, and one can use this as 
a motivational tool. Metabolic risks will decrease, and 
the patient should be encouraged to adopt a healthy 
lifestyle.
The World Health Organization (WHO) proposed a few 
strategies for weight loss.11 Initial management should 
involve dietary changes to restrict energy intake. Physical 
activities should be increased, which will lead to a 
decrease in visceral fat that is usually not altered by diet 
alone.
Behaviour modification includes the discussion of 
social habits, with special reference to smoking and 
alcohol consumption. Reduction of psychosocial stressors 
should also be attempted. These principles were applied 
in the Fertility Fitness Programme in Adelaide, Australia,45 
a programme involving weekly dietetic and psychological 
intervention in a group and multi-team approach for 6 
months, with remarkable success. Weight loss of 6.2 
kg was associated with restoration of ovulation in 12 
previously anovulatory women and pregnancy in 11 
women. A decrease in insulin resistance and testosterone 
was also observed.
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The timeframe for patients to lose weight should be 
realistic and should be discussed with them. Wadden50 
showed in 1993 that short-term energy restriction can 
result in rapid weight loss with improvement of the 
reproductive symptoms – but 90% of women will regain 
the lost weight.
Lifestyle modifications are non-invasive and frequently 
successful, and should be the initial treatment. The NIH 
document51 includes logical, multifaceted and easy-to-
implement guidelines to assist in planning effective 
weight loss in patients with obesity (Table IV).
Pharmacotherapy and surgical options should only 
be considered if no success has been achieved with the 
above strategies.52 Literature on the use of metformin to 
improve insulin sensitivity is becoming more available. 
Metformin acts primarily by inhibiting hepatic glucose 
output and increasing insulin sensitivity in peripheral 
tissues.53 In PCOS, metformin improves insulin resistance 
but also improves ovarian function, regulates cycles, 
lowers androgen levels and leads to an improvement 
in clinical hyperandrogenism. Some evidence seems 
promising regarding improved long-term outcomes, but 
unfortunately the studies are of short duration.54 For future 
recommendations, more evidence is still needed.
Natural progression of PCOS
Dahlgren2 and Elting et al.35 focused especially on the 
natural history of PCOS. From this information, it was 
learned that, towards menopause, resumption of menstrual 
cyclicity is often experienced. Androgen levels tend to fall 
and, with ovarian ageing and follicle loss, lower levels of 
inhibin B are present as well as an increase in follicle-
stimulating hormone (FSH).55 Despite these improvements 
in the reproductive system, metabolic risks remain a 
problem. These risks are related to obesity rather than 
menstrual cycle patterns. There is a trend for insulin 
resistance and hyperinsulinaemia to worsen over time, 
even in the presence of declining androgen levels.56
Conclusion
The importance of lifestyle modification, with weight loss 
as the mainstay of therapy, cannot be over-emphasised. 
Emotional support and the effectiveness of group therapy 
are of the utmost importance. Lifestyle modification 
remains the initial treatment of women with PCOS, with 
proven benefits in terms of fertility and metabolic risk 
reduction.
The mere diagnosis of PCOS in women, regardless of 
whether pregnancy is desired or not, is not sufficient. 
Any woman at any age with PCOS should be appropriately 
managed, informed and assessed for metabolic risks.
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